CD274 and cervical carcinoma: Several studies have evaluated rates of PD-L1 and PD-1 expression in cervical cancers with ranges reported between 34.4–96% [146,147,148] and 46.97–60.82% [149,150], respectively, making cervical cancer an attractive candidate for checkpoint inhibitors.